XML 73 R41.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Collaborative and Other Relationships (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration |
|  | For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat |  | $ | 109.3 |  |  | $ | 118.4 |  |  | $ | 264.9 |  |  | $ | 236.1 |
Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income |  | 54.7 |  |  | 59.2 |  |  | 132.5 |  |  | 118.0 |
Total sales and marketing expense incurred by the Lecanemab Collaboration |  | 29.0 |  |  | 5.6 |  |  | 68.3 |  |  | 15.6 |
Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 14.5 |  |  | 2.8 |  |  | 34.2 |  |  | 7.8 |
Summary of Activity Related to Aducanumab Collaboration | A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:
|  | For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Total ADUHELM development expense |  | $ | 34.6 |  |  | $ | 43.7 |  |  | $ | 116.0 |  |  | $ | 132.8 |
Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income |  | 19.0 |  |  | 24.0 |  |  | 63.8 |  |  | 73.0 |
Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement |  | (8.0) |  |  | 154.3 |  |  | 127.8 |  |  | 391.7 |
Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income |  | (3.9) |  |  | 83.3 |  |  | 68.1 |  |  | 211.2 |
Total ADUHELM collaboration third party milestones |  | — |  |  | — |  |  | — |  |  | 100.0 |
Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income |  | — |  |  | — |  |  | — |  |  | 45.0 |
Summary of Activity Related to Denali Therapeutics Collaboration | A summary of development expense related to this collaboration is as follows:
|  | For the Three Months Ended September 30, |  | For the Nine Months Ended September 30,
(In millions) |  | 2022 |  | 2021 |  | 2022 |  | 2021
Total Denali collaboration development expense |  | $ | 19.9 |  |  | $ | 8.5 |  |  | $ | 58.0 |  |  | $ | 27.2 |
Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income |  | 11.4 |  |  | 5.1 |  |  | 33.5 |  |  | 16.3 |

X
- Definition Summary of Activity Related to Denali Therapeutics Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration